Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Obesity drug inhibits prostate tumor growth

15.03.2004


Proteomics screen identifies novel prostate cancer target



The Burnham Institute’s Jeffrey Smith, Ph.D. has discovered that orlistat, commonly prescribed as an anti-obesity drug, has a positive side-effect: it inhibits cancer growth. Dr. Smith made this discovery using an activity-based proteomics screening technique developed in his laboratory that makes it possible to identify active targets and simultaneously screen for their inhibitors. These results will be published in the journal Cancer Research on March 15.

The metabolism of a tumor cell is different from its normal counterpart cell. Scientists have long suspected that metabolism is connected to tumor progression. Dr. Smith and co-workers designed a proteomics screen based on monitoring the activity of a family of enzymes--serine hydrolyases--involved in metabolism. They used their screen to compare normal prostate cells with prostate cancer cells and discovered that the prostate cancer cells are affected by an increased activity of fatty acid synthase. Fatty acid synthase is the enzyme that converts dietary carbohydrate to fat.


The screen also identified orlistat, marketed by Roche as XenicalTM, as an inhibitor of fatty acid synthase.

These discoveries, made in vitro, held true when tested in mice. When they administered orlistat to mice bearing prostate tumors, the Smith laboratory discovered that the drug was able to inhibit tumor growth in mice. Further experiments confirmed that orlistat has no effect on normal prostate cells and no apparent side effects in the mice; it acts specifically as fatty acid synthase.

Additional screening of breast cancer and colon cancer cells revealed that fatty acid synthase activity is upregulated in these tumors, as well, presenting the possibility of designing new treatments for these cancers based on inhibiting the enzyme’s activity with orlistat or a new drug based on orlistat’s inhibitory activity.

Orlistat was originally developed as an inhibitor of pancreatic lipase. Pancreatic lipase is a member of the same enzyme family--the serine hyrdolases--used in Smith’s screening. It is involved in processing of fats in the digestive tract, which is how the drug prevents adsorption of dietary fat.

The method developed by Dr. Smith represents a quantum leap in drug discovery. So-called "activity-based" proteomics screening is a new frontier in medical research, based on applying information gleaned from the human genome project. The ability to compile a comprehensive profile of a potential drug’s activities, revealing unintended activities along with the intended behaviors targeted by the drug offers a systematic way to simulate how a drug will work, before it is actually tested in animals and humans.

Given the time and cost inherent in developing new treatments, activity-based proteomics screening opens up a new route for finding effective treatments based on monitoring basic cell behaviors, such as metabolism or respiration.

Proteomics screening is an efficient way to determine proof of concept needed before a potential treatment can be refined for clinical trials: in a matter of weeks, Dr. Smith was able to glean the initial discovery that linked excessive fatty acid synthase activity with flawed metabolism in cancer cells, and identified orlistat as its inhibitor.

"This discovery with orlistat has given us a very nice wedge with which we can go in and perturb tumor cells and ask the question, ’What are the active targets, what are the other changes that take place when you inhibit fatty acid synthase?’", says Dr. Smith, "and that will give us really good insights into the mechanism, and we anticipate that’s going to reveal a whole swath of additional drug targets along this pathway. This is a big advance in the sense that we have an approved drug--approved for one indication--that has another target and another potential disease indication, prostate cancer."

Dr. Smith is Associate Scientific Director for Technology at The Burnham Institute, where he is also a Associate Professor in the Institute’s NCI-designated Cancer Center.

Co-authors contributing to this study include Drs. Steven J. Kridel and Fumiko Axelrod, postdoctoral fellows at The Burnham Institute, and Dr. Natasha Rozenkrantz of Activix Biosciences in La Jolla.


This research was supported by grants from the National Cancer Institute, and the Department of Defense’s Prostate Cancer Program.

The Burnham Institute is an independent, nonprofit, public benefit organization dedicated to basic biomedical research principally in the areas of cancer, aging, and the neurosciences. The Institute ranks consistently among the world’s most influential research organizations for the impact of its research in analyses conducted annually by the Institute for Scientific Information.

Nancy Beddingfield | EurekAlert!
Further information:
http://www.burnham-inst.org/

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>